<SEC-DOCUMENT>0001493152-24-047738.txt : 20241126
<SEC-HEADER>0001493152-24-047738.hdr.sgml : 20241126
<ACCEPTANCE-DATETIME>20241126070033
ACCESSION NUMBER:		0001493152-24-047738
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20241126
FILED AS OF DATE:		20241126
DATE AS OF CHANGE:		20241126

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			OKYO Pharma Ltd
		CENTRAL INDEX KEY:			0001849296
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		ORGANIZATION NAME:           	03 Life Sciences
		IRS NUMBER:				000000000

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-41386
		FILM NUMBER:		241498132

	BUSINESS ADDRESS:	
		STREET 1:		55 PARK LANE
		CITY:			LONDON
		STATE:			X0
		ZIP:			W1K 1NA
		BUSINESS PHONE:		44 (0) 207 495 2379

	MAIL ADDRESS:	
		STREET 1:		55 PARK LANE
		CITY:			LONDON
		STATE:			X0
		ZIP:			W1K 1NA
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>form6-k.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 4pt solid; border-bottom: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 18pt"><B>UNITED
STATES</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 18pt"><B>SECURITIES
AND EXCHANGE COMMISSION</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 12pt"><B>Washington,
D.C. 20549</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Rule-Page --><DIV STYLE="margin: 0pt auto; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 18pt"><B>FORM
6-K</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center">&nbsp;</P>

<!-- Field: Rule-Page --><DIV STYLE="margin: 0pt auto; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>REPORT
OF FOREIGN PRIVATE ISSUER</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>PURSUANT
TO RULE 13a-16 OR 15d-16</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>UNDER
THE SECURITIES EXCHANGE ACT OF 1934</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>November
2024</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Rule-Page --><DIV STYLE="margin: 0pt auto; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Commission
File Number:</B> 001-41386</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Rule-Page --><DIV STYLE="margin: 0pt auto; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 18pt"><B>OKYO
Pharma LTD</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Exact
Name of Registrant as Specified in Its Charter)</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Rule-Page --><DIV STYLE="margin: 0pt auto; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><B>9<SUP>th
</SUP>Floor</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><B>107
Cheapside</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><B>London</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><B>EC2V
6DN</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Address
of registrant&rsquo;s principal executive office)</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin: 0pt auto; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicate
by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form
20-F &#9746; Form 40-F &#9744;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicate
by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): &#9744;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicate
by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): &#9744;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid; border-bottom: Black 4pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>


<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>INFORMATION
CONTAINED IN THIS REPORT ON FORM 6-K</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
November 26, 2024, OKYO Pharma LTD (the &ldquo;<U>Company</U>&rdquo;) issued this 6K announcing today, that its CEO, Gary S. Jacob, Ph.D.,
will be participating in one on one meetings and a fireside chat at the 4th Annual Virtual BTIG Ophthalmology Day on Monday,
December 2nd, 2024. More than 20 public and private medical technology and biotechnology companies will be participating in BTIG&rsquo;s
event. Panel discussion topics will include exploring the latest developments and trends within ophthalmic medical technologies and therapeutics.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Announcement is furnished herewith as Exhibit 99.1 to this Report on Form 6-K. The information in the attached Exhibits 99.1 is being
furnished and shall not be deemed &ldquo;filed&rdquo; for the purposes of Section 18 of the Securities Exchange Act of 1934, or otherwise
subject to the liabilities of that Section, nor shall it be deemed incorporated by reference in any filing made by the Company under
the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, except as otherwise set forth herein or as shall be expressly
set forth by specific reference in such a filing.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>SIGNATURES</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned, thereunto duly authorized.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>OKYO
    Pharma LTD</B></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 5%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 45%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date:
    November 26, 2024</FONT></TD>
    <TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>/s/
    Keeren Shah</I></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Keeren
    Shah</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief
    Financial Officer</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 3; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>EXHIBIT
INDEX</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 0.75in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit
    No.</B></FONT></TD>
    <TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; width: 0.1in; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Description</B></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">99.1</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="ex99-1.htm">Announcement, dated November 26, 2024</A></FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 4; Options: Last -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"></P>


</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>ex99-1.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit
99.1</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><IMG SRC="ex99-1_001.jpg" ALT="" style="width:250px"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>OKYO
Pharma to Participate at the 4<SUP>th</SUP> Annual BTIG Ophthalmology Conference</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">London
and New York, NY, November 26, 2024. OKYO Pharma Limited (NASDAQ: OKYO), a clinical-stage biopharmaceutical company developing innovative
therapies for the treatment of neuropathic corneal pain (NCP), a severe ocular condition without an FDA approved therapy, and for inflammatory
dry eye disease (DED), a multi-billion-dollar market, is pleased to announce that its CEO, Gary S. Jacob, Ph.D., will be participating
in one on one meetings and a fireside chat at the 4<SUP>th</SUP> Annual Virtual BTIG Ophthalmology Day on Monday, December
2nd, 2024. More than 20 public and private medical technology and biotechnology companies will be participating in BTIG&rsquo;s
event. Panel discussion topics will include exploring the latest developments and trends within ophthalmic medical technologies and therapeutics.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Presentation
Information:</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Event:
</B>4<SUP>th</SUP> Annual BTIG Ophthalmology Day</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Participant:
</B>Dr. Gary S. Jacob, CEO of OKYO Pharma</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Date:
</B>Monday, December 2, 2024</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Fireside
Chat: </B>2:40-3:15pm</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
more information about the event, email <U>uscorporateaccess@btig.com</U>. Please note that participants must be pre-registered to attend.
To access BTIG insights, contact a firm representative or log in to <U>www.btigresearch.com</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>About
NCP</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Neuropathic
corneal pain (NCP) is a condition that causes pain and sensitivity of the eyes, face, or head. The exact cause of NCP is unknown but
thought to result from nerve damage to the cornea combined with inflammation. NCP, which can exhibit as a severe, chronic, or debilitating
condition in patients suffering from a host of ophthalmic conditions, is presently treated by various topical and systemic treatments
in an off-label fashion. There are no approved commercial treatments currently available for this condition.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>About
OK-101</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">OK-101
is a lipid conjugated chemerin peptide agonist of the ChemR23 G-protein coupled receptor which is typically found on immune cells of
the eye responsible for the inflammatory response. OK-101 was developed using a membrane-anchored-peptide technology to produce a novel
long-acting drug candidate for treating dry eye disease. OK-101 has been shown to produce anti-inflammatory and pain-reducing activities
in mouse models of dry eye disease and corneal neuropathic pain (NCP), respectively, and is designed to combat washout through the inclusion
of the lipid anchor built into the drug molecule to enhance the residence time of OK-101 within the ocular environment. OK-101 showed
clear statistical significance in multiple endpoints in a recently completed Phase 2, multi-center, double-masked, placebo-controlled
trial of OK-101 to treat DED, and is presently being evaluated in <FONT STYLE="background-color: white">a randomized, placebo-controlled,
double-masked Phase 2 trial to treat 48 NCP patients.</FONT></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>About
OKYO</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">OKYO
Pharma Limited (NASDAQ: OKYO) is a clinical stage biopharmaceutical company developing innovative therapies for the treatment of NCP
and DED, with ordinary shares listed for trading on the NASDAQ Capital Market. OKYO is focused on the discovery and development of novel
molecules to treat NCP and inflammatory DED. In addition to the recently completed Phase 2 trial of OK-101 to treat DED patients, OKYO
is also evaluating OK-101 to treat NCP patients with the just announced opening of a Phase 2 trial to treat the debilitating conditions
of NCP. For further information, please visit <U>www.okyopharma.com</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>Enquiries:</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 37%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>OKYO
    Pharma Limited</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 38%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Gary
    S. Jacob, Chief Executive Officer</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 25%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">917-497-7560</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Business
    Development &amp; Investor Relations</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Paul
    Spencer</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">+44
(0)20 7495 2379</FONT></P></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 1; Options: NewSection Last; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence -->-</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>ex99-1_001.jpg
<TEXT>
begin 644 ex99-1_001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" "* ED# 2(  A$! Q$!_\0
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MGV1X?\2:7XGT\7NEW*RQ]'7HR'T([5G_ ! U"ZTKP-JE[93-#<Q1@I(O53N
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M;MKS]G1I'8LZV@0D^SBOGVO<=-8M^SE?9[!@/^^UK2NOA]49T?M>AX=3X?\
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MNO!:7/:KG0=(O'+W.EV<K'JSPJ3_ "JL?"'AP]=#L/\ OPO^%>/?\- ZE_T
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M7-%\K81Y9*Z,3_A#O#?_ $ [#_OPM'_"'>&_^@'8?]^%K;HI<TNY7*NQB?\
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MTMSRJ]=U7RQV/6_@YX=,<5QKLZ,"X\J#/<?Q'^0KU*YNK>SA,US-'#&.K.P
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M?3!I+BYDPB#G S\JBN]^,OC;^V=6&AV,N;*S;]ZRGB23O^ _G5KX*^"O[0U
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MGW_A=/C3_G\MO_ 9:Y+Q!XAO_$VIG4-2,37)4*S1QA,XZ9Q7U?\ \(AX=_Z
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M_3UKY6N[74_"?B%H9-]M?V<N0PX((Z$>QK[)KSGXJ^ 5\4:2=0L8A_:MJN5
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..&_QK7HJG.3ZD\J['_]D!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
